---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-215180"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-09-06T23:59:59+00:00"
generated_at: "2026-05-31T06:05:13.868438+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Verrica confirms separation agreements with former CCO Joe Bonaccorso

## Summary
- On August 30, 2024, Verrica entered into Release and Consulting Agreements with former CCO Joe Bonaccorso.
- Terms of the agreements were disclosed on August 27, 2024 and remain unchanged.
- The agreements formalize Bonaccorso's departure as Chief Commercial Officer.

## SEC filing metadata
- accession: 0001193125-24-215180
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524215180/0001193125-24-215180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524215180/d894672d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-215180
- JSON: https://secwatch.observer/filing/0001193125-24-215180.json
- Plain text: https://secwatch.observer/filing/0001193125-24-215180.txt

## Key facts
- Executive change
  Joe Bonaccorso departed as Chief Commercial Officer at Verrica Pharmaceuticals Inc..
  - Action: departed
  - Role: Chief Commercial Officer
  source text: on August 30, 2024, the Company and Joe Bonaccorso, the Company’s former Chief Commercial Officer, entered into a Release Agreement and a Consulting Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524215180/0001193125-24-215180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.